ARKG vs BLV

ARK Genomic Revolution ETF vs Vanguard Long-Term Bond ETF

Quick take
  • BLV has the lower expense ratio at 0.00% vs 0.75% for ARKG.
  • BLV pays a higher dividend yield (4.77%).

Side-by-side metrics

MetricARKGBLV
Expense ratio
Annual fee. Lower is better.
0.75%0.00%
Dividend yield
Trailing 12-month yield.
0.00%4.77%
AUM
Assets under management — bigger funds are typically more liquid.
$1.24B$8.49B
YTD return
7.21%0.48%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
2.352.08
P/E ratio
Last price
$30.38$68.40
Inception
Issuer
ARKVanguard

ARKG top holdings

Top holdings · ARKG
TEMTempus AI Inc Class A common stock9.45%
TWSTTwist Bioscience Corp9.02%
CRSPCRISPR Therapeutics AG8.94%
TXG10x Genomics Inc Ordinary Shares - Class A5.78%
BEAMBeam Therapeutics Inc5.44%
ABSIAbsci Corp4.79%
NTRANatera Inc4.08%
ILMNIllumina Inc4.04%
NTLAIntellia Therapeutics Inc3.83%
PSNLPersonalis Inc3.59%
Sector breakdown · ARKG
Healthcare100.0%

BLV top holdings

Holdings data unavailable for BLV.

About ARKG

ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Tempus AI Inc Class A common stock (TEM), which represents 9.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About BLV

BLV (Vanguard Long-Term Bond ETF) is Long-term investment-grade bonds. Managed by Vanguard, the fund carries $8.5B in assets under management, an expense ratio of 0.00%, a dividend yield of 4.77%.